Event Details
NCI Cancer Moonshot Workshop
Apr 27 2021
On April 27 - 28, 2021, the National Cancer Institute Cancer Moonshot workshop on ‘Enhancing Systemic Drug Delivery to Tumors” will be held.
This workshop is organized under US President Joe Biden's Cancer Moonshot initiative which aims to accelerate cancer research and to make more therapies available for patients while also improving the ability to prevent cancer and detect it at an early stage. The Cancer Moonshot initiative has three ambitious goals: to accelerate scientific discovery in cancer, foster greater collaboration and improve the sharing of data.
Nanobiotix CEO, Laurent Levy will participate in the workshop on April 27 with a keynote presentation, followed by a panel discussion with other leading minds in oncology.
This workshop is organized under US President Joe Biden's Cancer Moonshot initiative which aims to accelerate cancer research and to make more therapies available for patients while also improving the ability to prevent cancer and detect it at an early stage. The Cancer Moonshot initiative has three ambitious goals: to accelerate scientific discovery in cancer, foster greater collaboration and improve the sharing of data.
Nanobiotix CEO, Laurent Levy will participate in the workshop on April 27 with a keynote presentation, followed by a panel discussion with other leading minds in oncology.
Agenda
Keynote presentation details
Workshop segment: Drug Delivery TechnologiesKeynote Title: The answer to how we enhance systemic drug delivery in cancer treatment lies within the question.
Abstract: How we enhance systemic drug delivery in cancer treatment is a large and noble question. Nanobiotix is challenging the premise through the principles of nanophysics. With the goal of improving treatment outcomes in mind, Laurent Levy and his team postulate a shift in approach that would alter the current paradigm of drug delivery.
Nanobiotix is developing a radioenhancer, consisting of modified hafnium oxide nanoparticles, that is delivered intratumorally. The technology—NBTXR3—has achieved proof of concept in a phase III study showing that its novel mechanism of action absorbs an increased amount of energy within tumor cells and delivers an enhanced radiotherapy dose, which induces significant physical destruction of tumor cells without increasing damage to surrounding healthy tissues. The Company is currently evaluating NBTXR3 for patients with head and neck cancer in a phase I dose expansion study, and has a phase III global registration study launch planned for this year. Early clinical evidence from a phase I study evaluating NBTXR3 plus anti-PD-1 as a local and systemic therapy suggests that NBTXR3 can destroy the injected tumor; prime adaptive immune response; improve the efficacy of anti-PD-1; and help overcome resistance to anti-PD-1 as well.
Additionally, Nanobiotix is seeking to change the paradigm of systemic drug delivery through wholly-owned subsidiary, Curadigm. Curadigm’s novel “nanoprimer” technology aims to overcome the challenges that intravenously-administered therapeutics face by directly targeting the liver. The nanoprimer is delivered via IV, prior to the therapeutic, temporarily occupying clearance pathways in the liver so that a higher percentage of the effective dose can reach the target without adding hepatic toxicity. Nanobiotix sees far-reaching implications for this technology in oncology and in any disease where IV therapeutics have an opportunity to help patients.
The Company has also invented a third nanotechnology platform that is being explored for CNS disorder.